Barbara Burtness

38.5k total citations · 10 hit papers
363 papers, 16.0k citations indexed

About

Barbara Burtness is a scholar working on Oncology, Otorhinolaryngology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Barbara Burtness has authored 363 papers receiving a total of 16.0k indexed citations (citations by other indexed papers that have themselves been cited), including 217 papers in Oncology, 182 papers in Otorhinolaryngology and 152 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Barbara Burtness's work include Head and Neck Cancer Studies (182 papers), Lung Cancer Treatments and Mutations (106 papers) and Cancer Immunotherapy and Biomarkers (59 papers). Barbara Burtness is often cited by papers focused on Head and Neck Cancer Studies (182 papers), Lung Cancer Treatments and Mutations (106 papers) and Cancer Immunotherapy and Biomarkers (59 papers). Barbara Burtness collaborates with scholars based in United States, Canada and Japan. Barbara Burtness's co-authors include Julie E. Bauman, Jennifer R. Grandis, Vivian Wai Yan Lui, C. René Leemans, Daniel E. Johnson, Ranee Mehra, Robert L. Ferris, Arlene A. Forastiere, John D. Cramer and Joseph P. Eder and has published in prestigious journals such as New England Journal of Medicine, JAMA and Nature Communications.

In The Last Decade

Barbara Burtness

352 papers receiving 15.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Head and neck squamous cell carcinoma

2020 2.5k citations Barbara Burtness, Julie E. Bauman et al. profile →
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

2016 1.3k citations Barbara Burtness, Ranee Mehra et al. profile →
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

2016 848 citations Barbara Burtness, Kenneth Emancipator et al. profile →
Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study

2005 656 citations Barbara Burtness, Meredith A. Goldwasser et al. Journal of Clinical Oncology profile →
Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin

2000 596 citations Barbara Burtness et al. Journal of Clinical Oncology profile →
The changing therapeutic landscape of head and neck cancer

2019 535 citations Barbara Burtness, Robert L. Ferris et al. profile →
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

2019 491 citations Ezra E.W. Cohen, R. Bryan Bell et al. profile →
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

2018 329 citations Ranee Mehra, Barbara Burtness et al. profile →
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group

2017 317 citations Shanthi Marur, Shuli Li et al. Journal of Clinical Oncology profile →
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update

2023 106 citations Aarti Bhatia, Barbara Burtness profile →

Peers

Countries citing papers authored by Barbara Burtness

Since Specialization

Citations

This map shows the geographic impact of Barbara Burtness's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Burtness with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Burtness more than expected).

Fields of papers citing papers by Barbara Burtness

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Burtness. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Burtness. The network helps show where Barbara Burtness may publish in the future.

Co-authorship network of co-authors of Barbara Burtness

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Burtness. A scholar is included among the top collaborators of Barbara Burtness based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Burtness. Barbara Burtness is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck 2025 ·Head & Neck ·Aarti Bhatia, Ranee Mehra, Jessica R. Bauman, Saad A. Khan, Wei Wei, Veronique Neumeister, Teresa Sandoval-Schaefer, R. Katherine Alpaugh, Miriam N. Lango, David L. Rimm, John A. Ridge, Barbara Burtness	2
2	Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer 2025 ·Journal of Clinical Oncology ·Barbara Burtness, Yael Flamand, Harry Quon, Gregory S. Weinstein, Ranee Mehra, (unknown), Seungwon Kim, Bert W. O’Malley, Enver Özer, Chukwuemeka Ikpeazu, Wayne M. Koch, Neil D. Gross, R. Bryan Bell, Mihir R. Patel, Miriam N. Lango, Luc G.T. Morris, Russell K. Smith, Daniel W. Karakla, Jeremy D. Richmon, F. Christopher Holsinger, Robert L. Ferris	4
3	Vaping and tumor metastasis: current insights and progress 2024 ·Cancer and Metastasis Reviews ·Yibo Xi, Lei Yang, Barbara Burtness, (unknown)	1
4	PLK1 Acts in Homologous Recombinatorial Repair and in Mitosis As Synthetically Lethal with the Fanconi Anemia/BRCA Pathway 2024 ·Blood ·Gary M. Kupfer, (unknown), Jian Li, Erica A. Golemis, Paul Young, (unknown), (unknown), Patrick Sung, Barbara Burtness	0
5	A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors. 2024 ·Journal of Clinical Oncology ·Georgina V. Long, Robert I. Haddad, Caroline Robert, Laurent Mortier, Dirk Schadendorf, Ravindra Uppaluri, Inge Marie Svane, Philippe Saïag, Annette M. Lim, (unknown), Richard A. Scolyer, Marya Chaney, Cecilie Abildgaard, Qasim Ahmad, François Ringeisen, Diane Opatt McDowell, Barbara Burtness	2
6	Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group. 2024 ·Journal of Clinical Oncology ·Barbara Burtness, Yael Flamand, Harry Quon, Gregory S. Weinstein, Ranee Mehra, Joaquín J. García, Seungwon Kim, Bert W. O’Malley, Enver Özer, Wayne M. Koch, Neil D. Gross, R. Bryan Bell, Mihir R. Patel, Miriam N. Lango, (unknown), Russell K. Smith, Daniel W. Karakla, Jeremy D. Richmon, F. Christopher Holsinger, Robert L. Ferris	4
7	Evaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerability 2023 ·JAAD International ·Annika Belzer, (unknown), (unknown), James Clune, Kelly Olino, Mario Sznol, Aarti Bhatia, Barbara Burtness, Sean R. Christensen, Jonathan S. Leventhal	1
8	106P Treatment sequencing in PD-L1–positive recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Exploratory analysis of the phase III KEYNOTE-048 study 2023 ·Immuno-Oncology Technology ·Richard Greil, Barbara Burtness, Simon Laban, Irene Braña, (unknown), Thorsten Fuereder, Åse Bratland, Lisa Licitra, Tamara Rordorf, Amanda Psyrri, Aron Popovtzer, Brett Hughes, Makoto Tahara, J. Lin, (unknown), (unknown), Kevin J. Harrington	1
9	Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-treatment DNA Methylation From Peripheral Blood 2022 ·International Journal of Radiation OncologyBiologyPhysics ·David C. Qian, Bryan C. Ulrich, Gang Peng, Hongyu Zhao, Karen N. Conneely, Andrew H. Miller, Deborah Watkins Bruner, Ronald C. Eldridge, Evanthia C. Wommack, Kristin Higgins, Dong M. Shin, Nabil F. Saba, Alicia K. Smith, Barbara Burtness, Henry S. Park, (unknown), Jonathan J. Beitler, Canhua Xiao	1
10	Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer 2020 ·Modern Pathology ·Kenneth Emancipator, Lingkang Huang, Deepti Aurora-Garg, (unknown), Ezra E.W. Cohen, Kevin J. Harrington, Denis Soulières, Christophe Le Tourneau, Lisa Licitra, Barbara Burtness, Ramona F. Swaby	71
11	Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck 2019 ·Clinical Cancer Research ·Jong Woo Lee, (unknown), Teresa Sandoval-Schaefer, Kyung Jin Eoh, Dong‐Hua Yang, Fang Zhu, Ranee Mehra, Roshan Sharma, Stephen G. Gaffney, Elizabeth B. Perry, Jeffrey P. Townsend, Ilya G. Serebriiskii, Erica A. Golemis, Natalia Issaeva, Wendell G. Yarbrough, Ja Seok Koo, Barbara Burtness	58
12	Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma 2019 ·Molecular Cancer Therapeutics ·Marta Baro, (unknown), Barbara Burtness, Mark A. Lemmon, Joseph N. Contessa	8
13	Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer 2017 ·Clinical Cancer Research ·Asel Biktasova, Michael Hajek, Andrew K. Sewell, (unknown), Gary Bellinger, Hari A. Deshpande, Aarti Bhatia, Barbara Burtness, Benjamin L. Judson, Saral Mehra, Wendell G. Yarbrough, Natalia Issaeva	46
14	E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group breakdown → 2017 ·Journal of Clinical Oncology ·Shanthi Marur, Shuli Li, Anthony J. Cmelak, Maura L. Gillison, Weiqiang Zhao, Robert L. Ferris, William H. Westra, Jill Gilbert, Julie E. Bauman, Lynne I. Wagner, David R. Trevarthen, (unknown), Barbara A. Murphy, Nishant Agrawal, A. Dimitrios Colevas, Christine H. Chung, Barbara Burtness	317
15	Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303 2014 ·Clinical Cancer Research ·Amanda Psyrri, Ju-Whei Lee, Eirini Pectasides, Maria Vassilakopoulou, Efstratios K. Kosmidis, Barbara Burtness, David L. Rimm, Harold J. Wanebo, Arlene A. Forastiere	24
16	Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303 2014 ·Clinical Cancer Research ·Ann Marie Egloff, Ju-Whei Lee, Corey J. Langer, Harry Quon, Alec Vaezi, Jennifer R. Grandis, Raja R. Seethala, Lin Wang, Dong M. Shin, Athanassios Argiris, Dong‐Hua Yang, Ranee Mehra, John A. Ridge, Urjeet A. Patel, Barbara Burtness, Arlene A. Forastiere	26
17	Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers 2013 ·Clinical Cancer Research ·Ranee Mehra, Fang Zhu, Dong‐Hua Yang, Kathy Q. Cai, JoEllen Weaver, Mahendra Singh, Anna S. Nikonova, Erica A. Golemis, Douglas B. Flieder, Harry S. Cooper, Miriam N. Lango, John A. Ridge, Barbara Burtness	21
18	Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients 2010 ·Cancer Epidemiology Biomarkers & Prevention ·Christine H. Chung, Erin H. Seeley, Heinrich Röder, Julia Grigorieva, Maxim Tsypin, (unknown), Barbara Burtness, Athanassios Argiris, Arlene A. Forastiere, Jill Gilbert, Barbara A. Murphy, Richard M. Caprioli, David P. Carbone, Ezra E.W. Cohen	51
19	Nuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better Prognosis 2010 ·Clinical Cancer Research ·Eirini Pectasides, (unknown), Clarence T. Sasaki, Panteleimon Kountourakis, Barbara Burtness, George Fountzilas, Urania Dafni, Thomas Zaramboukas, Θεόδωρος Ράμπιας, David L. Rimm, Jennifer R. Grandis, Amanda Psyrri	58
20	Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study breakdown → 2005 ·Journal of Clinical Oncology ·Barbara Burtness, Meredith A. Goldwasser, William A. Flood, Bassam Mattar, Arlene A. Forastiere	656

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact